Cargando…
Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine
The challenge of COVID-19 has rapidly changed medical management worldwide. The relatively small time from pandemic to vaccines regulatory approval triggered a race toward vaccines development. However, important questions regarding SARS-CoV-2 vaccines remain. A case of complete Vogt-Koyanagi-Harada...
Autores principales: | Saraceno, Janaína Jamile Ferreira, Souza, Guilherme Macedo, dos Santos Finamor, Luciana Peixoto, Nascimento, Heloisa Moraes, Belfort, Rubens |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404022/ https://www.ncbi.nlm.nih.gov/pubmed/34462013 http://dx.doi.org/10.1186/s40942-021-00319-3 |
Ejemplares similares
-
Azd-1222: Vogt-Koyanagi-Harada syndrome: case report
Publicado: (2021) -
AZD 1222: Vogt Koyanagi Harada syndrome: case report
Publicado: (2022) -
Vogt-Koyanagi-Harada disease following ChAdOx1 nCoV-19 and mRNA-1273 vaccination
por: Rujkorakarn, P., et al.
Publicado: (2023) -
Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice
por: Stebbings, Richard, et al.
Publicado: (2021) -
Treatment of Vogt-Koyanagi-Harada Disease
por: Alaql, Musab K, et al.
Publicado: (2020)